Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Ajman Government Media Office hosts Foreign Affairs Undersecretary at THE SIGNAL with a clear message: ‘The UAE does not seek the signal – it creates it’

    November 22, 2026

    Humaid bin Ammar attends day two of Ajman Media Forum 2026 and honours participants and partners

    November 22, 2026

    Ajman Government Media Office’s THE SIGNAL forum features Saeed Al Eter on how public trust and a successful development model underpin UAE soft power in times of crisis

    November 22, 2026
    • Automotive
    • Business
    • Entertainment
    • Health
    • Luxury
    • News
    • Lifestyle
    • Sports
    • Technology
    • Travel
    Arab DispatchArab Dispatch
    • Home
    • Contact Us
    Arab DispatchArab Dispatch
    Home » Moderna reduces 2025 revenue forecast as COVID vaccine demand wanes
    Business

    Moderna reduces 2025 revenue forecast as COVID vaccine demand wanes

    January 13, 2025
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    Moderna Inc. experienced a sharp 18% drop in stock value on Monday after the company significantly reduced its 2025 revenue forecast by $1 billion. The biotech firm now projects revenue between $1.5 billion and $2.5 billion for 2025, a decline from its earlier guidance of $2.5 billion to $3.5 billion issued in September. The revised forecast reflects multiple challenges, including falling demand for its COVID-19 vaccine and increased competition in the market.

    Moderna reduces 2025 revenue forecast as COVID vaccine demand wanes

    Jamey Mock, Moderna’s Chief Financial Officer, highlighted uncertainties influencing the outlook, including shrinking vaccination rates and intensified competition, particularly from Novavax, which recently partnered with Sanofi to co-commercialize its COVID-19 vaccine globally. Moderna’s share of the U.S. retail COVID-19 vaccine market dropped to 40% in 2024 from 48% in 2023, signaling further challenges in retaining market dominance.

    The company also noted a broader decline in vaccination rates, down 7% year-over-year in the U.S. retail sector. Additional factors include potential delays in manufacturing agreements and uncertainty surrounding revaccination recommendations for respiratory syncytial virus (RSV) from the Centers for Disease Control and Prevention (CDC). Despite these hurdles, Moderna plans to cut cash expenses by $1 billion in 2025, with further cost reductions of $500 million anticipated in 2026.

    This announcement follows a steep decline in demand for Moderna’s COVID-19 vaccine, Spikevax, which generated $6.7 billion in revenue in 2023, down from $18 billion in 2022. The company’s newly launched RSV vaccine, mResvia, has yet to generate significant sales. Total revenue for 2024 reached approximately $3.1 billion, meeting earlier projections but highlighting the sharp contraction in pandemic-related demand.

    Looking forward, Moderna aims to diversify its portfolio with plans to launch 10 new products within the next three years, including a next-generation COVID-19 vaccine and a combination flu-COVID shot. The company anticipates securing regulatory approval for three products in 2025 alone, reinforcing its reliance on messenger RNA (mRNA) technology as a core driver of innovation. Despite these efforts, the announcement has sparked concerns about Moderna’s ability to sustain long-term growth, particularly as the company expects to burn over $3 billion in cash during 2025.

    Moderna’s stock, already under pressure, has declined more than 60% over the past 12 months. This plunge reflects broader market skepticism about the company’s post-pandemic trajectory, even as broader biotechnology indices like the iShares Biotechnology ETF and the S&P 500 have shown mixed performances over the same period. The revenue guidance adjustment and cost-cutting initiatives were announced ahead of Moderna’s presentation at the JPMorgan Healthcare Conference, a pivotal event for the industry that could shape investor sentiment further. – By MENA Newswire News Desk.

    Related Posts

    Chip boom lifts South Korea into $1 trillion export club

    November 21, 2026

    Botswana reviews proposed 33% power tariff hike today

    November 19, 2026

    Petrol price jump lifts South Africa inflation as SARB weighs rates

    November 18, 2026

    AfDB backs Morocco reforms and climate resilience with €434.4m

    November 14, 2026

    DP World partner ATI wins 25-year Manila port renewal

    November 13, 2026

    ADB flags $264 billion yearly ASEAN infrastructure gap

    November 12, 2026
    Editor's Pick

    Guinea declares mpox outbreak over after 42 days without cases

    November 21, 2026

    WFP seeks $12.1 billion to feed 91 million people in 2027

    November 21, 2026

    Chip boom lifts South Korea into $1 trillion export club

    November 21, 2026

    Air Arabia Egypt launches Cairo to Al Ain flights now

    November 20, 2026

    Botswana reviews proposed 33% power tariff hike today

    November 19, 2026

    PM Modi meets Prince and Princess of Wales in New Delhi

    November 19, 2026

    DXB handles 50.4 million passengers in first nine months

    November 18, 2026

    Congo Ebola death toll reaches 5,568 as cases pass 11,000

    November 18, 2026
    © 2026 Arab Dispatch | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.